KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Labcorp Holdings (LH) EBITDA (2016 - 2025)

Labcorp Holdings' EBITDA history spans 17 years, with the latest figure at $267.6 million for Q4 2025.

  • For Q4 2025, EBITDA rose 23.6% year-over-year to $267.6 million; the TTM value through Dec 2025 reached $1.4 billion, up 27.42%, while the annual FY2025 figure was $1.4 billion, 27.42% up from the prior year.
  • EBITDA for Q4 2025 was $267.6 million at Labcorp Holdings, down from $396.6 million in the prior quarter.
  • Across five years, EBITDA topped out at $1.1 billion in Q1 2021 and bottomed at -$122.8 million in Q4 2023.
  • The 5-year median for EBITDA is $323.6 million (2024), against an average of $379.2 million.
  • The largest annual shift saw EBITDA soared 649.27% in 2021 before it plummeted 530.88% in 2023.
  • A 5-year view of EBITDA shows it stood at $519.7 million in 2021, then tumbled by 94.52% to $28.5 million in 2022, then tumbled by 530.88% to -$122.8 million in 2023, then skyrocketed by 276.3% to $216.5 million in 2024, then grew by 23.6% to $267.6 million in 2025.
  • Per Business Quant, the three most recent readings for LH's EBITDA are $267.6 million (Q4 2025), $396.6 million (Q3 2025), and $394.5 million (Q2 2025).